Valuation : Tarsus Pharmaceuticals, Inc.

Market Cap 3.98B 3.43B 3.23B 2.95B 5.51B 376B 5.53B 38.11B 14.79B 193B 14.96B 14.63B 622B P/E 2026 *
-42.6x
P/E 2027 * 39x
Enterprise Value 3.98B 3.43B 3.23B 2.95B 5.51B 376B 5.53B 38.11B 14.79B 193B 14.96B 14.63B 622B EV / Sales 2026 *
5.58x
EV / Sales 2027 * 4.31x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
1 day+9.10%
1 week+26.51%
Current month+22.28%
1 month+48.55%
3 months+50.45%
6 months+19.13%
Current year+10.87%
1 week 70.71
Extreme 70.71
91.53
1 month 57.63
Extreme 57.63
91.53
Current year 53.89
Extreme 53.89
91.53
1 year 48.2
Extreme 48.2
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 2018-08-31
Director of Finance/CFO 64 2023-04-23
Chief Tech/Sci/R&D Officer 47 2024-11-03
Director TitleAgeSince
Chairman 48 2022-12-01
Director/Board Member 71 2019-11-30
Director/Board Member 80 2016-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/24/26 Exercice

Director

2,766 0.0065%
3/20/26 Sell

Chief Operating Officer

2,989 0.0070%
3/17/26 Sell

Head of Human Resources

12,274 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
+9.10%+26.51% - - 3.65B
Average +9.10%
Weighted average by Cap. +9.10%

Financials

2026 *2027 *
Net sales 714M 614M 578M 528M 987M 67.38B 990M 6.83B 2.65B 34.57B 2.68B 2.62B 111B 925M 796M 749M 684M 1.28B 87.37B 1.28B 8.85B 3.44B 44.82B 3.47B 3.4B 144B
Net income -95.74M -82.38M -77.51M -70.8M -132M -9.04B -133M -916M -355M -4.64B -359M -352M -14.94B 116M 99.75M 93.85M 85.73M 160M 10.94B 161M 1.11B 430M 5.62B 435M 426M 18.09B
Net Debt - -
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
26-09-04 $90.78 +9.10% 1,595,936
26-09-03 $83.21 +0.54% 733,746
26-09-02 $82.76 +11.76% 1,899,864
26-09-01 $74.05 -0.26% 587,273
26-08-31 $74.24 +3.46% 711,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
90.78USD
Average target price
94.00USD
Spread / Average Target
+3.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TARS Stock